$20.36
1.04% yesterday
Nasdaq, Aug 21, 10:00 pm CET
ISIN
US0327241065
Symbol
ANAB

AnaptysBio, Inc. Target price 2025 - Analyst rating & recommendation

AnaptysBio, Inc. Classifications & Recommendation:

Buy
83%
Hold
17%

AnaptysBio, Inc. Price Target

Target Price $46.41
Price $20.36
Potential
Number of Estimates 13
13 Analysts have issued a price target AnaptysBio, Inc. 2026 . The average AnaptysBio, Inc. target price is $46.41. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 15 Analysts recommend AnaptysBio, Inc. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the AnaptysBio, Inc. stock has an average upside potential 2026 of . Most analysts recommend the AnaptysBio, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 91.28 66.99
431.93% 26.61%
EBITDA Margin -125.26% -160.75%
86.26% 28.33%
Net Margin -159.10% -225.88%
83.31% 41.97%

13 Analysts have issued a sales forecast AnaptysBio, Inc. 2025 . The average AnaptysBio, Inc. sales estimate is

$67.0m
Unlock
. This is
45.61% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$150m 21.53%
Unlock
, the lowest is
$27.2m 77.90%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $91.3m 431.93%
2025
$67.0m 26.61%
Unlock
2026
$83.3m 24.39%
Unlock
2027
$104m 24.25%
Unlock
2028
$112m 8.08%
Unlock
2029
$160m 42.93%
Unlock
2030
$298m 86.58%
Unlock
2031
$423m 41.86%
Unlock
2032
$569m 34.37%
Unlock

4 Analysts have issued an AnaptysBio, Inc. EBITDA forecast 2025. The average AnaptysBio, Inc. EBITDA estimate is

$-108m
Unlock
. This is
25.85% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-83.1m 2.88%
Unlock
, the lowest is
$-129m 51.19%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-114m 26.90%
2025
$-108m 5.82%
Unlock
2026
$-105m 2.94%
Unlock
2027
$-122m 16.82%
Unlock

EBITDA Margin

2024 -125.26% 86.26%
2025
-160.75% 28.33%
Unlock
2026
-125.43% 21.97%
Unlock
2027
-117.93% 5.98%
Unlock

13 AnaptysBio, Inc. Analysts have issued a net profit forecast 2025. The average AnaptysBio, Inc. net profit estimate is

$-151m
Unlock
. This is
14.12% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-86.3m 34.88%
Unlock
, the lowest is
$-192m 45.12%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-145m 11.24%
2025
$-151m 4.19%
Unlock
2026
$-142m 6.46%
Unlock
2027
$-156m 10.24%
Unlock
2028
$-184m 17.85%
Unlock
2029
$-133m 27.81%
Unlock
2030
$-41.0m 69.10%
Unlock
2031
$170m 515.31%
Unlock
2032
$342m 100.84%
Unlock

Net Margin

2024 -159.10% 83.31%
2025
-225.88% 41.97%
Unlock
2026
-169.86% 24.80%
Unlock
2027
-150.70% 11.28%
Unlock
2028
-164.32% 9.04%
Unlock
2029
-82.99% 49.49%
Unlock
2030
-13.74% 83.44%
Unlock
2031
40.23% 392.79%
Unlock
2032
60.14% 49.49%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -5.12 -5.41
15.79% 5.66%
P/E negative
EV/Sales 4.54

13 Analysts have issued a AnaptysBio, Inc. forecast for earnings per share. The average AnaptysBio, Inc. EPS is

$-5.41
Unlock
. This is
17.61% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.09 32.83%
Unlock
, the lowest is
$-6.88 49.57%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-5.12 15.79%
2025
$-5.41 5.66%
Unlock
2026
$-5.06 6.47%
Unlock
2027
$-5.58 10.28%
Unlock
2028
$-6.57 17.74%
Unlock
2029
$-4.75 27.70%
Unlock
2030
$-1.47 69.05%
Unlock
2031
$6.09 514.29%
Unlock
2032
$12.23 100.82%
Unlock

P/E ratio

Current -4.43 19.16%
2025
-3.76 15.05%
Unlock
2026
-4.02 6.91%
Unlock
2027
-3.65 9.20%
Unlock
2028
-3.10 15.07%
Unlock
2029
-4.29 38.39%
Unlock
2030
-13.89 223.78%
Unlock
2031
3.34 124.05%
Unlock
2032
1.66 50.30%
Unlock

Based on analysts' sales estimates for 2025, the AnaptysBio, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.47 88.85%
2025
4.54 83.92%
Unlock
2026
3.65 19.61%
Unlock
2027
2.94 19.52%
Unlock
2028
2.72 7.48%
Unlock
2029
1.90 30.03%
Unlock
2030
1.02 46.41%
Unlock
2031
0.72 29.51%
Unlock
2032
0.54 25.57%
Unlock

P/S ratio

Current 4.63 86.25%
2025
8.51 83.86%
Unlock
2026
6.84 19.61%
Unlock
2027
5.51 19.52%
Unlock
2028
5.09 7.48%
Unlock
2029
3.56 30.04%
Unlock
2030
1.91 46.41%
Unlock
2031
1.35 29.51%
Unlock
2032
1.00 25.58%
Unlock

Current AnaptysBio, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
UBS
Locked
Locked
Locked Aug 12 2025
Wedbush
Locked
Locked
Locked Aug 07 2025
JP Morgan
Locked
Locked
Locked Jul 24 2025
HC Wainwright & Co.
Locked
Locked
Locked Jun 04 2025
Guggenheim
Locked
Locked
Locked May 28 2025
Guggenheim
Locked
Locked
Locked May 06 2025
Wedbush
Locked
Locked
Locked May 01 2025
Analyst Rating Date
Locked
UBS:
Locked
Locked
Aug 12 2025
Locked
Wedbush:
Locked
Locked
Aug 07 2025
Locked
JP Morgan:
Locked
Locked
Jul 24 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jun 04 2025
Locked
Guggenheim:
Locked
Locked
May 28 2025
Locked
Guggenheim:
Locked
Locked
May 06 2025
Locked
Wedbush:
Locked
Locked
May 01 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today